Architect Therapeutics, Inc.
- Biotech or pharma, therapeutic R&D
We formed Architect in 2023 with a $120M Series A led by ARCH. Our goal is to drug challenging targets with chemistry breakthroughs from Jin-Quan Yu and Ben Cravatt at Scripps Research. Our lead program in immunology (a PPI disruptor) is entering DC this year, and our earlier pipeline includes highly validated targets in immunology, oncology, and neuroscience. Our technology turns dormant C-H bonds, the most common bonds in small molecules, into powerful building blocks of novel drug architectures difficult to access before. Our discovery engine integrates three pillars – DNA encoded libraries, nano-scale synthesis covalent libraries, and chemical proteomics – to maximally leverage our novel chemistry to address a broad range of targets and mechanisms.
Address
San DiegoCalifornia
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}